Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer.

about

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q44669628

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@en

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@nl

type

Item

label

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@en

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@nl

prefLabel

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@en

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@nl

P1476

Meta-analysis of efficacy and ...... ic non-small cell lung cancer.

@en

P2093

Fei Li

http://www.w3.org/2001/XMLSchema#string

Li-Min Pang

http://www.w3.org/2001/XMLSchema#string

Shu-Hua Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative efficacy and tolerability of three treatments in old people with osteoporotic vertebral compression fracture: a network meta-analysis and systematic review

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Erlotinib in previously treated non-small-cell lung cancer

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China.

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Graphical tools for network meta-analysis in STATA.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

P304

86816-86827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19735

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29156837

http://www.w3.org/2001/XMLSchema#string

P932

5689727

http://www.w3.org/2001/XMLSchema#string